{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-129487","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.929536+00:00","generated_at":"2026-05-29T21:23:56.834727+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Perspective Therapeutics reports positive Phase 1/2a data for [212Pb]VMT-α-NET in NETs; pursuing dose escalation","bullets":["No dose-limiting toxicities observed at 2.5 and 5.0 mCi doses; safety profile favorable.","Eight of nine patients had durable disease control; six of nine had measurable tumor reduction, one confirmed RECIST response.","Safety Monitoring Committee recommends dose escalation to Cohort 3; company to engage with FDA.","Plans to file IND for PSV359 (FAP-α targeting) by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-129487","json":"https://secwatch.observer/filing/0000950170-24-129487.json","markdown":"https://secwatch.observer/filing/0000950170-24-129487.md","text":"https://secwatch.observer/filing/0000950170-24-129487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017024129487/0000950170-24-129487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017024129487/catx-20241121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T21:23:56.834727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}